Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 14;22(20):11101. doi: 10.3390/ijms222011101

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Visualized enrichment networks of gene ontology analysis of good/poor prognosis specific mRNA expression. (A) Gene ontology analysis of unfavorable risk for the differentially expressed genes (DEGs) between the good patient outcome group and poor patient outcome group in ACC with ALT. (B) TF targeted gene network in unfavorable risk ACC with ALT. Top 5 enriched pathways showing significant difference (FDR = 0.001). (C) Heatmap of correlation value between peptide secretion signature genes (n = 27) and transcriptional factors (CBX3, NRF1, EP300, and NFYB) (pink: positive correlation, blue: negative correlation). (D) Gene ontology analysis of favorable risk of PAAD with ALT. (E) Heatmap of correlation matrix between antigen processing (n = 21) and transcriptional factors (EP300, HDAC2, CEBPB, HIF4G, HIF4A, ZBTB7A, and RXRA). (F) Gene ontology analysis of favorable risk of HNSC with ALT. (G) Heatmap of correlation matrix between myeloid leukocyte activation (n = 45) and transcriptional factors (E2F4, NFE2, BATF, SPI1, NFIC, TFDP1, ELF1, and FOXM1). (H) Gene ontology analysis of unfavorable risk of GBM with NDTMM. (I) Gene ontology analysis of favorable risk GBM with ALT.